The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancerRyan Finnegan, David A. Gewirtz|Frontiers in Oncology|2023Cited by 23